EN DE
Watch Elite Pharma Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Elite Pharma Inc (ELTP) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Elite Pharma Inc stock $0.68, price $0.24, upside +183.3%, quality 76 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

EP Elite Pharma Inc logo Thin data Nov 9, 2026

Elite Pharma Inc

ELTP · US
Undervalued, but in a downtrend

The stock costs 65% less than our calculation considers fair.

Fair value $0.6800 · Strongly undervalued
Quality 76/100
Highly profitable · 40.2% net margin (TTM)
Low debt
Generates free cash flow
Ranks above peers (11/13)
Wide moat 72/100
Even on cautious assumptions the value is 71% above the price ($0.4100).
Mixed Growth (revenue 5y +42.4 %/yr in USD)
Insiders bought $34,680 (6M)
Thin data
Watch Elite Pharma Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.7700 $0.0290 Fair Value $0.6800 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

60‑month range $0.0290 – $0.7700 · fair‑value band $0.4100 – $0.8400 · the $0.2400 price screens below the $0.6800 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 9, 2026.

Follow Elite Pharma in your weekly email

Every Wednesday you see whether Elite Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals.

Show moreShow less

The company operates through Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals segments.

It owns, licenses, manufactures, and sales of generic, oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases.

In addition, the company provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with sequestered Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products.

Additionally, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products.

The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Stock analysis

Elite Pharma Inc (ELTP) currently trades at $0.2400, while our model-based Fair Value estimate is $0.6800, implying the stock looks roughly 65% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $1.94 per share, and 23 of the 24 models we run sit above the $0.2400 price.

Bear case: the Asset-Based group reads lowest at $0.0700, and 1 of the 24 models stay below the price. Data coverage for this calculation is low.

Scenario range: $0.4100 (bear) to $0.8400 (bull), the price of $0.2400 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 76/100 (high quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2018: revenue and profit before it include the divested business. Growth is measured afresh from 2018.

Elite Pharma Inc reported revenue of $149M in FY2026 versus $32.3M in FY2022, a compound +46.6%/yr. Reported net income was $44.9M in FY2026, compounding +49.9%/yr from FY2022.

Key figures

Market cap $259M Micro · P/E ratio 6.0 · P/S ratio 1.83 · EPS (TTM) $0.0400 · Net margin 40.2% · Return on equity 74.3% · Return on assets (EBIT) 1,007% (5-year average) · Operating margin 23.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 72 out of 100 (medium confidence).

What moves the price

The share trades about 65% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 183%, ELTP screens cheaper than that median.

Fair Value models

Bear $0.4100 Fair Value $0.6800 Bull $0.8400
Price $0.2400 · Upside +183.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then ($0.0244 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $0.3100 $0.4400 $0.8200 75
EPV $0.3500 $0.4000 $0.4300 74
Growth DCF $0.2900 $0.4800 $0.7800 74
All 24 models by family
DCF Models
FCF DCF $0.3100 $0.4400 $0.8200 75
Owner Earnings $0.2900 $0.5700 $1.08 70
5Y Revenue Exit $0.3300 $0.5600 $1.05 67
5Y EBITDA Exit $0.4600 $0.8300 $1.56 69
5Y P/E Exit $0.5900 $1.36 $2.42 65
10Y Revenue Exit $0.3100 $0.6700 $0.9000 64
10Y EBITDA Exit $0.4100 $0.9300 $1.85 62
10Y P/E Exit $0.5000 $1.17 $2.31 58
Earnings-Based
Graham-Dodd $0.2800 $1.98 $2.77 61
Lynch FV $1.02 $1.46 $1.90 59
PEG = 1.0 $1.02 $1.46 $1.90 55
EPV $0.3500 $0.4000 $0.4300 74
Multiples
P/E Multiple $0.6900 $0.9200 $1.15 63
P/S Multiple $0.3600 $0.4800 $0.6000 58
P/B Multiple $0.2800 $0.3800 $0.4700 55
EV/EBIT $0.5900 $0.7900 $0.9900 66
EV/EBITDA $0.5100 $0.6800 $0.8400 67
EV/Revenue $0.2900 $0.4100 $0.5400 53
Asset-Based
NCAV (Graham) $0.0400 $0.0700 $0.0800 55
Growth DCF
Growth DCF $0.2900 $0.4800 $0.7800 74
Rev-Margin DCF $0.3600 $0.6400 $1.22 67
Economic Profit
Residual Income $0.2300 $0.3700 $0.9800 59
ROIC Compounder $0.4100 $0.5500 $0.7000 70
Growth Earnings
Growth-Adj P/E $1.35 $1.94 $2.52 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 76/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 96
How much profit the company makes from its sales and capital
Quality Growth 95
Are margins and returns getting better?
Cashflow 57
Do the profits arrive as real cash?
Financial strength 94
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 54
How calm the share price moves, does not count
Price momentum 3
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 67
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $34,680, on Oct 9, 2026.

  • BuyBarry H DashDirector2× since Aug 19, 2026: 130,000 shares, avg. $0.2668$34,680Oct 9, 2026

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2018: revenue and profit before it include the divested business. Growth is measured afresh from 2018.
Revenue growth 1 year
+77.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−83.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.4%
Start year 2021 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+45.4%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+50.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+50.7%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.42.5% vs 6.9%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 34%
Pace: the 5-year rate starts in 2021 (pandemic)

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+2.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −0.3% a year for the price.

Watch ELTP, get fair value alerts →

Compare Elite Pharma Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 76 · Top 25%
Fair Value upside +183.3% · Top 25%
Profitability
Return on equity (12 months) 74.3% · Top 25%
Return on assets 32.5% · Top 25%
Net margin (12 months) 40.2% · Top 25%
Operating margin (12 months) 23.3% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −19.5% · Bottom 25%
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 6.0× · Cheapest 25%
P/B 2.61× · Pricier than median
P/S (12 months) 1.83× · Cheaper than median
Price / free cash flow (fiscal year) 11.3× · Cheapest 25%
EV/EBITDA 6.2× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 15
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)100 · sector 29
HEALTH (low debt)99 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $113.53 +43% vs ELTP
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs ELTP
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs ELTP
Haleon plc HLN $9.14 $8.61 −6% vs ELTP
Merck KGaA MRK €148.75 €109.18 −27% vs ELTP
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs ELTP
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs ELTP
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs ELTP
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs ELTP
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs ELTP

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Elite Pharma Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Elite Pharma Inc Fair Value". https://www.fairvalue-calculator.com/stock/ELTP

Frequently asked questions

Is Elite Pharma Inc (ELTP) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of $0.6800 versus a price of $0.2400, about +183% upside (undervalued).
What is the fair value of ELTP?
Our model-based fair value for Elite Pharma Inc is $0.6800 (as of Nov 9, 2026), built from audited fundamentals. The current price: $0.2400.
What is the quality score of ELTP?
Elite Pharma Inc has a Quality Score of 76/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Elite Pharma Inc (ELTP)?
Our model-based price target is the fair value of $0.6800 (as of Nov 9, 2026) from 24 valuation models. Cautious scenario $0.4100, optimistic scenario $0.8400. It is a calculation from audited fundamentals, not an analyst target.
What is the Elite Pharma Inc stock forecast for 2026?
Our models put fair value at $0.6800, about +183% upside versus a price of $0.2400 (undervalued). Cautious scenario $0.4100, optimistic scenario $0.8400. The calculation is refreshed regularly with new filings.
What is the revenue of Elite Pharma Inc (ELTP)?
Elite Pharma Inc reported trailing-twelve-month revenue of about $141M (latest available figure, as of Nov 9, 2026).
What growth is priced into Elite Pharma Inc (ELTP)?
For today's price to be fair in a discounted-cash-flow model, Elite Pharma Inc would have to grow free cash flow by +2.1 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +42.5 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of ELTP use?
Our models discount Elite Pharma Inc at 11.2 %: a base by market capitalisation (micro), damped by beta 0.33, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Elite Pharma Inc that is +2.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.2 %) and the same formula as our fair value.
How much growth has Elite Pharma Inc (ELTP) delivered so far?
Over the past 5 years revenue at Elite Pharma Inc grew +42.5 % a year. The price currently implies free-cash-flow growth of +2.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Elite Pharma Inc (ELTP) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Elite Pharma Inc (+2.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Elite Pharma Inc (ELTP)?
The free-cash-flow yield on the price is 8.83 %: that much free cash flow Elite Pharma Inc produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Elite Pharma Inc (ELTP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Elite Pharma Inc it is $0.6800 per share (as of Nov 9, 2026), against a price of $0.2400. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Elite Pharma Inc stock overvalued or undervalued in 2026?
As of Nov 9, 2026, ELTP trades below its calculated fair value: price $0.2400, fair value $0.6800, a gap of about +183% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ELTP?
No. The price is what the market pays today ($0.2400); the fair value is what the company's own numbers justify ($0.6800). For Elite Pharma Inc the two are $0.4400 per share apart. That gap is exactly why we show both numbers side by side.
How much is Elite Pharma Inc worth?
The market values Elite Pharma Inc at about $259M (market capitalisation, as of Nov 9, 2026). Per share that is $0.2400; our models calculate a fair value of $0.6800 per share.
What do the bullish and bearish scenarios say about ELTP?
Our models span a range for Elite Pharma Inc: cautious scenario $0.4100, base $0.6800, optimistic $0.8400 per share (as of Nov 9, 2026, price $0.2400). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ELTP?
Elite Pharma Inc trades at a price-to-earnings ratio of 6.0 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.6800 is built from several models across several years. Median P/E at fiscal year-end, 6 fiscal years (2017 to 2026), reported earnings, FY2021, FY2023 ex one-offs: 8.3. Other multiples: P/B 2.6, P/S 1.8, EV/EBITDA 6.2.
How solid is the balance sheet of Elite Pharma Inc (ELTP)?
Balance-sheet figures for Elite Pharma Inc (as of Nov 9, 2026): return on equity 74.3%, debt of 0.03 per unit of equity. They feed the Quality Score of 76/100, which measures business quality independently of the share price.
How far is ELTP from its 52-week high?
Elite Pharma Inc trades at $0.2400, about 65% below its 52-week high of $0.6800 and 8% above the low of $0.2225 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.6800 is for.
Which stocks are comparable to Elite Pharma Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Elite Pharma Inc stock attractive at the current price?
The data as of Nov 9, 2026: price $0.2400, calculated fair value $0.6800 (+183%), Quality Score 76/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ELTP calculated?
We run Elite Pharma Inc through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $0.6800 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Elite Pharma Inc currently trades 65% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Elite Pharma Inc (ELTP)?
The closing price on Nov 6, 2026 was $0.2400. Our model-based fair value is $0.6800, about +183% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Elite Pharma Inc right now?
The rarer combination: high quality (76/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case ($0.4100). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.4100 to $0.8400) leaves room in how you read the outcome.

Key figures of Elite Pharma Inc

How large is the market capitalisation of Elite Pharma Inc (ELTP)?
The market capitalisation of Elite Pharma Inc is $259M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Elite Pharma Inc (ELTP)?
The price-to-sales ratio of Elite Pharma Inc is 1.83 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Elite Pharma Inc (ELTP)?
Earnings per share at Elite Pharma Inc are $0.0400 (price ÷ EPS = P/E 6.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Elite Pharma Inc (ELTP)?
The net margin of Elite Pharma Inc is 40.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Elite Pharma Inc (ELTP)?
The return on equity (ROE) of Elite Pharma Inc is 74.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Elite Pharma Inc (ELTP)?
On an EBIT basis the return on assets of Elite Pharma Inc is 1,007% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Elite Pharma Inc (ELTP)?
The operating margin of Elite Pharma Inc is 23.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Elite Pharma Inc (ELTP)?
Revenue at Elite Pharma Inc is growing −19.5% versus a year earlier (3y avg −83.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Elite Pharma Inc (ELTP)?
Earnings per share at Elite Pharma Inc are growing −38.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Elite Pharma Inc (ELTP) carry?
The net debt of Elite Pharma Inc is $470K (fiscal year 2024, ≈ 0.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Elite Pharma Inc in the live analysis

One click puts Elite Pharma Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.